

Date: 29.07.2022

To,

BSE Limited  
P. J. Towers, Dalal Street  
Mumbai – 400001

Dear Sir,

**Sub:** Outcome of Board Meeting held on 29.07.2022

**Ref:** Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of M/s. Hindustan Bio Sciences Limited held on Friday, 29.07.2022 at 02:00 P.M. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, considered and approved the following items of business:

- 1 Un-audited financial results of the company for the quarter ended 30-06-2022 placed before the board for their consideration
- 2 The Board has decided to fix date, place and time for conducting 30<sup>th</sup> Annual General Meeting of the company for the Financial Year ended 31-03-2022, along with the approval of Board Report and Notice for conducting of the Annual General Meeting on 30<sup>th</sup> September, 2022 is hereby given.
- 3 Secretarial Audit Report for the Financial Year 31-03-2022 has been discussed and the Board has noted the same.
- 4 Mr. VBSS Prasad, Practicing Company Secretary (C.P.No.4605), has been appointed as a scrutinizer for conducting E-voting in the ensuing Annual General Meeting.
- 5 Appointment of new auditor M/s. VASG & Associates in place of M/s. C Ramachandram & Company retiring auditors.
- 6 The board has reviewed the Limited Review Report for quarter ended 30.06.2022 and taken a note of the same.

The meeting concluded at 3-30 PM

This is for your information and records.

Thanking you.

For and on behalf of  
**Hindustan Bio Sciences Limited**



**J Varun Varma**  
Director  
(DIN: 00515430)



**HINDUSTAN BIO SCIENCES LIMITED**  
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034  
 Phone No. 23555161, Fax 40205171  
**STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2022**

Sl. No.	Particulars	Quarter ended			Rs. In Lakhs
		30.06.2022	31.03.2022	30.06.2021	Year ended
		(unaudited)	(Audited)	(unaudited)	31.03.2022
1	Income from Operations				
	(a) Revenue from operations				
	(b) Other Income	27.14	0.27	19.42	43.65
	Total Revenue ( 1 )	-	-	-	5.24
2	Expenses	27.14	0.27	19.42	48.89
	(a) cost of material consumed				
	(b) Purchases of Stock -in-trade				
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	18.29	-	13.03	28.93
	(d) Employee Benefit Expenses				
	(e) Finance Costs	5.93	5.94	6.06	24.05
	(f) Selling Expenses	0.03	0.22	0.07	0.50
	(g) Depreciation and amortisation Expenses	0.33	-	0.23	0.61
	(h) Other Expenses	0.10	0.10	0.08	0.34
	Total Expenses( 2 )	4.97	32.19	7.49	45.91
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	29.65	38.45	28.96	100.34
4	Exceptional items	(2.51)	(38.18)	(7.54)	(51.45)
5	Profit/(Loss) before tax(3 -4)	-	-	-	-
6	Tax Expenses	(2.51)	(38.18)	(7.54)	(51.45)
	(a) Current Tax				
	(b) Previous Taxes				
	(c) Deferred Tax				0.03
7	Profit /(Loss) for the period from continuing operations(5-6)	-	0.34	-	0.34
8	Profit /(Loss) from discontinued operations	(2.51)	(38.52)	(7.54)	(51.76)
9	Tax Expense of discontinued operations				
10	Profit /(Loss) from Discontinued operations after tax(8-9)				
11	Profit/(Loss) for the period(7+10)	(2.51)	(38.52)	(7.54)	(51.76)
12	Other Comprehensive Income				
	A (1) Items that will not be reclassified to profit or loss				
	(2) Income tax relating to items that will not be re- classified to profit or loss				
	B (1) Items that will be reclassified to profit or loss				
	(2) Income tax relating to items that will be reclassified to profit or loss				
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	(2.51)	(38.52)	(7.54)	(51.76)
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				(946.37)
16	Earnings per equity share for continuing operations				
	(A) Basic	(0.02)	(0.38)	(0.07)	(0.50)
	(B) Diluted	(0.02)	(0.38)	(0.07)	(0.50)
17	Earnings per equity share for discontinuing operations				
	(A) Basic	-	-	-	-
	(B) Diluted	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations				
	(A) Basic	(0.02)	(0.38)	(0.07)	(0.50)
	(B) Diluted	(0.02)	(0.38)	(0.07)	(0.50)

**Notes:**

- The Un-Audited Financial Results were taken on record by the Board of Directors in their meeting held on 29.07.2022.
- Previous Year figures have been regrouped wherever necessary.

for Hindustan Bio-Sciences Limited  
  
 J. Varun Verma  
 Director  
 (DIN:00515480)





**C. RAMACHANDRAM & CO.**  
**CHARTERED ACCOUNTANTS**

Plot No. 539, Souhiti Samridhi,  
2nd Floor, Kakatiya Hills,  
Madhapur, Hyderabad - 500 081.  
Phone : 040-42212099  
E-mail : crcoca@gmail.com  
Web : www.crcoca.in

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE  
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
M/S HINDUSTAN BIO SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s HINDUSTAN BIO SCIENCES LIMITED** (the "Company"), for the quarter and period ended June 30, 2022, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: July 29, 2022

**For C RAMACHANDRAM & CO.,**  
Chartered Accountants  
FR No. 002864S



*N. Madhusudan Reddy*  
**N MADHUSUDAN REDDY**  
Partner  
Membership No. 241624  
UDIN: 22241624ANVSZY9257